We are live on ! Find out more
TRV

Third Rock Ventures Portfolio holdings

AUM $1.07B
1-Year Est. Return 170.23%
This Fund
S&P 500
This Quarter Est. Return
+45.77%
1 Year Est. Return
+170.23%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$564M
AUM Growth
+$211M
Cap. Flow
+$51.5M
Cap. Flow %
9.13%
Top 10 Hldgs %
100%
Holding
4
New
1
Increased
–
Reduced
1
Closed
–

Top Buys

Rank Stock Value
1
CARM
Carisma Therapeutics
CARM
+$72.5M

Top Sells

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
1
Agios Pharmaceuticals
AGIO
$2.38B
$218M 38.62%
5,564,414
– –
FMI
2
DELISTED
Foundation Medicine, Inc.
FMI
$213M 37.7%
6,569,645
– –
CARM
3
DELISTED
Carisma Therapeutics
CARM
$78.6M 13.93%
+242,080
New +$72.5M
BLUE
4
DELISTED
bluebird bio
BLUE
$55M 9.74%
186,590
-69,249
-27% -$21M

Similar funds

AH
Achievement Holdings Chicago, Illinois $1.2B AUM 9.2% 1-Year Est. Return
GHF
Good Harbor Financial Barrington, Illinois $916M AUM 5.96% 1-Year Est. Return
CWA
Constellation Wealth Advisors New York $903M AUM 2.38% 1-Year Est. Return
RI
Relational Investors San Diego, California $840M AUM 0.57% 1-Year Est. Return
TCM
Tamarack Capital Management Carlsbad, California $840M AUM 19.47% 1-Year Est. Return
F
FutureAdvisor San Francisco, California $617M AUM 6.57% 1-Year Est. Return
MCC
Mid Continent Capital Chicago, Illinois $1.54B AUM 0.7% 1-Year Est. Return
OA
OFI Advisors Philadelphia, Pennsylvania $1.55B AUM 1.44% 1-Year Est. Return

Third Rock Ventures's Q1 2014 Portfolio in Review

As of Q1 2014, Third Rock Ventures held 4 positions worth $564M, up 60% from $353M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Third Rock Ventures deployed $51.5M of net new capital in Q1 2014, opening 1 new position. Its largest new stake was Carisma Therapeutics: 242,080 shares worth $78.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was bluebird bio, an estimated $21M trimmed.

  • Third Rock Ventures's largest Q1 2014 buy was Carisma Therapeutics: 242,080 shares worth $78.6M.
  • Third Rock Ventures's biggest Q1 2014 reduction was bluebird bio, cutting an estimated $21M.
  • Third Rock Ventures's ten largest holdings make up 100% of its $564M portfolio in Q1 2014.
  • Third Rock Ventures opened 1 new position and closed 0 in Q1 2014.
  • Third Rock Ventures's portfolio value rose 60% quarter-over-quarter to $564M.

Based on Third Rock Ventures's 13F filing for Q1 2014, filed 30 Apr 2014.